• Decoy Therapeutics corrected a Sept. 22, 2026 release on its warrant inducement transaction.
• New unregistered warrants for up to 2,368,868 shares are not subject to stockholder approval.
• Warrants will become exercisable immediately upon issuance, not upon any stockholder vote.
• New Warrants will expire five years from the issuance date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609221814PR_NEWS_USPR_____NE54598) on September 22, 2026, and is solely responsible for the information contained therein.